 |
Top 100 medical and healthcare startups in USA
Updated: May 09, 2024 | Editor: Jason Kwon |
1
Funding: $3.7B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
3
Funding: $3.4B
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
4
Funding: $3B
Altos Labs is working on biological reprogramming technology to essentially prolong human life
Altos Labs is working on biological reprogramming technology to essentially prolong human life
5
Funding: $2.4B
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
6
Funding: $2.3B
Bright Health provides tech-enabled consumer insurance plans for individuals across the country.
Bright Health provides tech-enabled consumer insurance plans for individuals across the country.
7
Funding: $2.1B
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
8
Funding: $2.1B
Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
9
Funding: $2B
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
10
Funding: $2B
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
11
Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
13
Funding: $1.6B
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
14
Funding: $1.6B
Oscar is a health insurance company that employs technology, design, and data to humanize health care.
Oscar is a health insurance company that employs technology, design, and data to humanize health care.
15
Funding: $1.6B
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
16
Funding: $1.5B
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
17
Funding: $1.5B
Calico is Google's research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.
Calico is Google's research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.
18
Funding: $1.5B
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
19
Funding: $1.5B
Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
20
Funding: $1.4B
Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.
Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.
21
Funding: $1.4B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
22
Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
23
Funding: $1.3B
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
24
Funding: $1.2B
TP Therapeutics is a clinical-stage biopharmaceutical company that is focusing on overcoming drug resistance in precision medicines for cancer and other diseases.
TP Therapeutics is a clinical-stage biopharmaceutical company that is focusing on overcoming drug resistance in precision medicines for cancer and other diseases.
25
Funding: $1.2B
Pillo Health is a healthcare solutions provider that empowers organizations to deliver better care into the home.
Pillo Health is a healthcare solutions provider that empowers organizations to deliver better care into the home.
26
Funding: $1.2B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
27
Funding: $1.2B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
28
Funding: $1.2B
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
29
Funding: $1.2B
ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
30
Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
31
Funding: $1.1B
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
32
Funding: $1.1B
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
33
Funding: $1.1B
Dermira is a development-stage biotech company focused on developing and commercializing innovative new therapies in dermatology.
Dermira is a development-stage biotech company focused on developing and commercializing innovative new therapies in dermatology.
34
Funding: $1.1B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
35
Funding: $1B
NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions.
NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions.
36
Funding: $1B
Hinge Health is pioneering digital care programs for people with chronic musculoskeletal conditions such as back or joint pain
Hinge Health is pioneering digital care programs for people with chronic musculoskeletal conditions such as back or joint pain
37
Funding: $1B
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
38
Funding: $999.6M
Cue Health develops and manufactures medical diagnostic products which are used in clinical and at-home settings.
Cue Health develops and manufactures medical diagnostic products which are used in clinical and at-home settings.
39
Funding: $1B
Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
40
Funding: $1B
SpringWorks Therapeutics is a biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer.
SpringWorks Therapeutics is a biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer.
41
Funding: $1B
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
42
Funding: $974.1M
Zymergen engineers better microbes that make useful molecules, which are part of all the materials in our daily lives. We are engineering biology predictably, reliably and to levels of performance unattainable through traditional R&D methods. Our comprehensive approach brings together technology, automation, and biology with the most sophisticated capabilities in each.
Zymergen engineers better microbes that make useful molecules, which are part of all the materials in our daily lives. We are engineering biology predictably, reliably and to levels of performance unattainable through traditional R&D methods. Our comprehensive approach brings together technology, automation, and biology with the most sophisticated capabilities in each.
43
Funding: $967.1M
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
44
Funding: $951.1M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
45
Funding: $946.4M
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
46
Funding: $941M
Sema4 is a patient-centered predictive health company and a leader in diagnostic testing. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Sema4 is a patient-centered predictive health company and a leader in diagnostic testing. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
47
Funding: $931.6M
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
48
Funding: $925.9M
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
49
Funding: $917.7M
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
50
Funding: $910.1M
Lyra is transforming mental health care by creating a frictionless experience for members, providers, and employers. Using technology and data, we connect companies and their employees to mental health providers and treatments that work.
Lyra is transforming mental health care by creating a frictionless experience for members, providers, and employers. Using technology and data, we connect companies and their employees to mental health providers and treatments that work.
